Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clincians. 2018;68(6):394–424. doi: 10.3322/caac.21492..
DOI: 10.3322/caac.21492
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf
Li T., Kang G., Wang T., Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687-702. doi: 10.3892/ol.2018.8733..
DOI: 10.3892/ol.2018.8733
Wang L., Chang Y., Xu J., Zhang Q. Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients. Biomed Res Int. 2016;2016:8103019. doi: 10.1155/2016/8103019..
DOI: 10.1155/2016/8103019
Scartozzi M., Giampieri R., Loretelli C., Bittoni A., Mandolesi A., Faloppi L. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancerpatients. Pharmacogenomics. 2013;14(16):1991-1998. doi: 10.2217/pgs.13.185..
DOI: 10.2217/pgs.13.185
Lv Y., Song L., Chang L., Zhang X., Liu Y., Liu W. Effect of bevacizumab combined with chemotherapy at different sequences in the gastriccancer-bearing nude mice. J Cancer Res Ther. 2018;14(8):190-196. doi: 10.4103/0973-1482.171364..
DOI: 10.4103/0973-1482.171364
Ohtsu A., Shah M..A, Van Cutsem E., Rha S.Y., Sawaki A., Park S.R. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. Journal of Clinical Oncology. 2011;29(30):3968–3976. DoI: 10.1200/JCO.2011.36.2236..
DOI: 10.1200/JCO.2011.36.2236
Shen L., Li J., Xu J., Pan H., Dai G., Qin S., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168–176. doi: 10.1007/s10120-014-0351-5..
DOI: 10.1007/s10120-014-0351-5
Fuchs C.S., Shitara K., Di Bartolomeo M. et al.; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5..
DOI: 10.1016/S1470-2045(18)30791-5
Van Cutsem E., de Haas S., Kang Y.K., Ohtsu A., et al. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. J Clin Oncol. 2012;30(17):2119-2127. doi: 10.1200/JCO.2011.39.9824..
DOI: 10.1200/JCO.2011.39.9824
Scartozzi M., Loretelli C., Galizia E., Mandolesi A., Pistelli M., Bittoni A., et al. Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One. 2012;7(7):e38192. doi: 10.1371/journal.pone.0038192..
DOI: 10.1371/journal.pone.0038192
Li J., Qin S., Xu J., Guo W., Xiong J., Bai Y., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology. 2013; 1 26):3219–3225. doi: 10.1200/JCO.2013.48.8585..
DOI: 10.1200/JCO.2013.48.8585
Liu L., Ma X.L., Xiao Z.L., Li M., Cheng S.H., Wei Y.Q. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer. 2012;13(7):3089-3097. doi: 10.7314/apjcp.2012.13.7.3089..
DOI: 10.7314/apjcp.2012.13.7.3089
Enzinger P.C., Fidias P., Meyerhardt J., et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Poster A68 presented at the ASCO Gastrointestinal Cancers Symposium; San Francisco, CA. January 26-28, 2006.
Yang L., Jiang X., Yan H., Li Y., Zhen H., Chang B., Kariminia S., Li Q. Irinotecan-containing doublet treatmentversus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018;18:43. doi: 10.1186/s12876-018-0772-4..
DOI: 10.1186/s12876-018-0772-4